Aflibercept high-dose - a case series
Aflibercept high-dose - a case series
About this item
Full title
Aflibercept high-dose - a case series
Author / Creator
Publisher
BioMed Central Ltd
Journal title
BMC ophthalmology, 2024-12, Vol.24 (1)
Language
English
Formats
Publication information
Publisher
BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Background Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg. Despite a safety profile comparable to aflibercept 2 mg in pivotal and phase 3 studies, reporting such cases in clinical practice helps evaluate potential ri...
Alternative Titles
Full title
Aflibercept high-dose - a case series
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A818750453
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A818750453
Other Identifiers
ISSN
1471-2415
E-ISSN
1471-2415
DOI
10.1186/s12886-024-03788-w
How to access this item
Log in as a Library member
